Every Form 4 that Tandem Diabetes Care, Inc. (TNDM) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow TNDM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TNDM filings page.
TANDEM DIABETES CARE INC (TNDM) reported insider equity activity by EVP & Chief Financial Officer Leigh Vosseller on August 15, 2026. Two blocks of restricted stock units (RSUs) covering 1,496 and 2,624 underlying shares were converted into common stock, and related RSU entries were removed.
Vosseller acquired 1,496 and 2,624 shares of common stock through these RSU vestings at a conversion price of $0.00 per share. A total of 537 and 942 shares were then withheld by Tandem Diabetes Care at $22.72 per share to satisfy tax withholding obligations; footnotes state that no shares were sold. Following these transactions, 25,580 shares of common stock are reported as held indirectly in the Leigh A. Vosseller Trust, for which Vosseller serves as trustee.
For TANDEM DIABETES CARE INC (TNDM), President & CEO John F. Sheridan reported the vesting and settlement of restricted stock units on August 15, 2026. Two RSU grants covering 5,982 and 9,934 units, awarded under the company’s 2023 Long-Term Incentive Plan, were converted into an equal number of common shares at no exercise price. To cover associated tax withholding on these vestings, the issuer withheld 3,044 and 5,055 common shares at a reference value of $22.72 per share; according to the disclosure, these were not open-market sales but shares retained by the company for tax purposes.
TANDEM DIABETES CARE INC (TNDM) reported insider equity activity by executive officer Susan Morrison, EVP & Chief Admin. Officer. On 2026-08-15, 2,827 shares of common stock were acquired through the vesting and conversion of restricted stock units, while 809 shares were withheld by the issuer to satisfy tax withholding obligations at $22.72 per share. Footnotes state that no shares were sold in the market; the transactions reflect equity compensation vesting and related tax withholding rather than open-market trading.
TANDEM DIABETES CARE INC (TNDM) executive Jean-Claude Kyrillos reported the vesting of restricted stock units and related share movements. On 2026-08-15, 1,010 RSUs granted on May 30, 2025 under the 2023 Long-Term Incentive Plan were converted into 1,010 shares of common stock. Of these, 535 shares were withheld by the company at $22.72 per share to satisfy tax withholding requirements, with no shares sold in the market, leaving a net 475 shares issued. Following the RSU vesting event, Kyrillos holds 7,067 RSUs that will continue to vest in eight equal quarterly installments, subject to the plan’s terms.
TANDEM DIABETES CARE INC (TNDM) reported that EVP and Chief Strategy Officer Elizabeth Anne Gasser exercised 3,014 Restricted Stock Units into an equal number of shares of common stock on August 15, 2026. Of these, 1,618 shares of common stock were withheld at $22.72 per share to satisfy tax withholding requirements upon RSU vesting, and the company notes that no shares were sold in the market. Following these transactions, 33,109 shares of common stock are reported as held indirectly through The Gasser Family Trust, where she is a co-trustee.
TANDEM DIABETES CARE INC (TNDM) reported insider equity activity by EVP & Chief Technology Officer Rick Carpenter. On August 15, 2026, he exercised 2,507 Restricted Stock Units, receiving an equal number of common shares at $0.00 per share. Of these, 1,277 shares of common stock were withheld at $22.72 per share to satisfy tax withholding requirements upon RSU vesting, and the company states that no shares were sold. The RSUs were granted under Tandem’s 2023 Long-Term Incentive Plan and vest over time in quarterly installments.
TANDEM DIABETES CARE INC (TNDM) reported that EVP & Chief Legal Officer Shannon Marie Hansen had 3,014 Restricted Stock Units vest and convert into an equal number of common shares on 2026-08-15. Of these, 1,535 shares were withheld at $22.72 per share to cover tax obligations, with no open‑market sales. A separate indirect holding of 1,935 common shares is reported in the Shannon M. Hansen Trust.
Tandem Diabetes Care EVP & Chief Operating Officer Jean-Claude Kyrillos reported equity compensation activity. On July 15, 2026, 3,636 restricted stock units converted into common stock, bringing his direct holdings to 31,741 shares. To satisfy tax withholding on the vesting, the company withheld 1,926 shares at $15.28 per share; no shares were sold in the market. After this vesting, 14,545 RSUs from a July 2024 grant under the 2023 Long-Term Incentive Plan remain outstanding.
Tandem Diabetes Care executive Elizabeth Anne Gasser reported gift transfers of company common stock. On June 2, she disposed of a total of 14,320 shares as bona fide gifts, including a transfer from her direct holdings to The Gasser Family Trust dated September 1, 2011 for no consideration. After these transactions, the trust holds 33,109 shares indirectly with Gasser as co-trustee, and her reported direct common stock holdings are 0 shares. These are non-market, estate-planning type movements rather than open-market sales.
Sheridan John F reported acquisition or exercise transactions in this Form 4 filing.
Tandem Diabetes Care reported that President and CEO John F. Sheridan received a grant of 191,103 restricted stock units (RSUs). Each RSU represents the right to receive one share of common stock or cash under the company’s 2023 Long-Term Incentive Plan.
One-third of the RSUs will vest on May 29, 2027, with the remaining units vesting in eight equal quarterly installments on the 15th of the month thereafter, encouraging longer-term alignment between the CEO and shareholders.
Gasser Elizabeth Anne reported acquisition or exercise transactions in this Form 4 filing.
Tandem Diabetes Care Inc. reported that EVP and Chief Strategy Officer Elizabeth Anne Gasser received a grant of 29,136 restricted stock units (RSUs). Each RSU represents a contingent right to one share of common stock or cash, at the company’s discretion, under the 2023 Long-Term Incentive Plan.
All 29,136 RSUs are held directly and bring her reported RSU holdings in this award to 29,136 units. One-third of the RSUs will vest on May 29, 2027, with the remaining units vesting in eight equal quarterly installments on the 15th of the month thereafter, subject to the plan’s terms. This is a compensation-related equity award, not an open-market purchase or sale.
Vosseller Leigh reported acquisition or exercise transactions in this Form 4 filing.
Tandem Diabetes Care executive vice president and chief financial officer Leigh Vosseller received a grant of 62,657 restricted stock units (RSUs) under the company’s 2023 Long-Term Incentive Plan. Each RSU represents a contingent right to receive one share of common stock or cash at the company’s discretion.
One-third of the RSUs will vest on May 29, 2027, with the remaining units vesting in eight equal quarterly installments on the 15th of the month thereafter, subject to plan terms and continued eligibility. This is a stock-based compensation award, not an open-market share purchase or sale.
Kyrillos Jean-Claude reported acquisition or exercise transactions in this Form 4 filing.
Tandem Diabetes Care executive vice president and chief operating officer Jean-Claude Kyrillos received a grant of 29,136 restricted stock units (RSUs). Each RSU represents a contingent right to one share of common stock or cash under the company’s 2023 Long-Term Incentive Plan.
One-third of these RSUs will vest on May 29, 2027, with the remaining units vesting in eight equal quarterly installments on the 15th of the month thereafter, subject to plan terms. Following this grant, Kyrillos directly holds 29,136 RSUs linked to common stock.
Morrison Susan reported acquisition or exercise transactions in this Form 4 filing.
Tandem Diabetes Care executive Susan Morrison received a grant of 29,136 restricted stock units as part of equity compensation. Each RSU represents a right to receive one share of common stock or cash under the company’s 2023 Long-Term Incentive Plan. One-third of the RSUs will vest on May 29, 2027, with the remaining units vesting in eight equal quarterly installments on the 15th of the month thereafter, contingent on plan terms and continued service. Following this award, Morrison holds 29,136 RSUs directly.
Carpenter Rick reported acquisition or exercise transactions in this Form 4 filing.
Tandem Diabetes Care EVP & Chief Technology Officer Rick Carpenter received a grant of 26,003 restricted stock units (RSUs). Each RSU represents a right to receive one share of common stock or cash, under the company’s 2023 Long-Term Incentive Plan. One-third of the RSUs will vest on May 29, 2027, with the remaining units vesting in eight equal quarterly installments thereafter, subject to plan terms and continued service.
Hansen Shannon Marie reported acquisition or exercise transactions in this Form 4 filing.
Tandem Diabetes Care executive Shannon Marie Hansen, EVP & Chief Legal Officer, received a grant of 29,136 restricted stock units (RSUs). Each RSU represents a contingent right to one share of common stock or cash under the company’s 2023 Long-Term Incentive Plan.
One-third of the 29,136 RSUs will vest on May 29, 2027, with the remaining units vesting in eight equal quarterly installments on the 15th of the month thereafter, subject to the plan’s terms. Following this grant, Hansen holds 29,136 RSUs directly from this award.
Tandem Diabetes Care Chair Emeritus Dick Allen reported routine equity compensation activity. On May 20, 2026, he received a grant of 10,220 restricted stock units (RSUs), each representing a contingent right to one share of common stock or cash under the company’s 2023 Long-Term Incentive Plan. These RSUs will vest on the one-year anniversary of the grant, subject to plan terms.
On May 21, 2026, 8,759 previously granted RSUs vested and converted into the same number of common shares, increasing his directly held common stock to 28,146 shares after the transaction. A separate line shows 22,757 common shares held indirectly through the Allen Family Trust dated October 12, 1981.
Tandem Diabetes Care director Peyton R. Howell reported equity award activity. On May 21, 2026, 8,759 previously granted restricted stock units vested and were exercised into the same number of common shares, increasing direct holdings to 29,836 shares. On May 20, 2026, Howell also received a new grant of 10,220 restricted stock units under the company’s 2023 Long-Term Incentive Plan, which will vest on the one-year anniversary of the grant date.
Tandem Diabetes Care director Joao Paulo Falcao Malagueira increased his equity stake through stock-based compensation. On May 21, 2026, 8,759 restricted stock units granted on May 21, 2025 vested and converted into 8,759 shares of common stock. Following this vesting, he directly holds 22,458 common shares.
Separately, on May 20, 2026 he received a new grant of 10,220 restricted stock units under the company’s 2023 Long-Term Incentive Plan. These RSUs each represent a contingent right to receive one share of common stock or cash, and will vest on the one-year anniversary of the grant date.
Beaver Sandra reported acquisition or exercise transactions in this Form 4 filing.
Tandem Diabetes Care Inc. reported that director Sandra Beaver received a grant of 5,110 restricted stock units on May 20, 2026. Each RSU represents a contingent right to one share of common stock or cash, and the award will fully vest on the one-year anniversary of the grant date.
Tandem Diabetes Care director Rajwant Sodhi reported equity compensation activity. He received a grant of 10,220 restricted stock units (RSUs) on May 20, 2026, which will vest on the one-year anniversary of that date under the company’s 2023 Long-Term Incentive Plan.
Separately, 8,759 previously granted RSUs vested and converted into common shares, increasing his direct common stock holdings to 24,280 shares. These transactions reflect stock-based compensation and derivative exercises rather than open-market buying or selling.
Tandem Diabetes Care director Kathleen McGroddy-Goetz reported compensation-related equity activity. She received a grant of 10,220 restricted stock units (RSUs) on May 20, 2026, which will vest on the one-year anniversary of the grant under the company’s 2023 Long-Term Incentive Plan.
Separately, 8,759 RSUs granted on May 21, 2025 fully vested and converted into common shares. Following these transactions, she directly holds 26,612 shares of common stock. All reported moves are equity awards and RSU vesting, with no open-market buying or selling.
Tandem Diabetes Care director Rebecca B. Robertson received 10,220 restricted stock units (RSUs) on May 20, 2026 under the company’s 2023 Long-Term Incentive Plan. A prior grant of 8,759 RSUs from May 21, 2025 vested and converted into 8,759 common shares on its one-year anniversary, bringing her direct holdings to 22,542 shares.
Tandem Diabetes Care director Christopher J. Twomey reported equity compensation activity. On May 20, 2026, he received a grant of 10,220 Restricted Stock Units (RSUs), each representing a contingent right to one share of common stock or cash under the 2023 Long-Term Incentive Plan.
On May 21, 2026, a prior grant of 8,759 RSUs (awarded on May 21, 2025) fully vested and converted into common shares, increasing his directly held common stock to 24,434 shares. Additional common shares are held indirectly by the Chris J. Twomey and Rebecca J. Twomey Family Trust and by Twomey Family Investments, LLC, where he shares voting and investment power and disclaims beneficial ownership except for his proportionate pecuniary interest.
Tandem Diabetes Care director Myoungil Cha increased equity exposure through stock-based compensation. On May 21, 2026, 8,759 previously granted restricted stock units vested and converted into the same number of common shares under the company’s 2023 Long-Term Incentive Plan. On May 20, 2026, Cha also received a new award of 10,220 restricted stock units that will vest on the one-year anniversary of that grant, subject to plan terms. Following these transactions, Cha directly owns 22,458 shares of common stock.
Tandem Diabetes Care EVP & Chief Technology Officer Rick Carpenter reported routine equity compensation activity involving restricted stock units and an employee stock purchase plan. On May 15, 2026, he acquired 1,336 shares of common stock at $10.90 through the company’s employee stock purchase plan and vested RSUs that converted into shares.
To cover tax obligations on these RSU vestings, 4,466 shares were withheld by the company at $12.82 per share, and footnotes clarify that no shares were sold in the market. After all transactions, Carpenter directly held 25,979 shares of Tandem Diabetes Care common stock.
Tandem Diabetes Care executive Elizabeth Anne Gasser reported several compensation-related stock transactions dated May 15, 2026. She exercised restricted stock units into a total of 10,267 shares of common stock at a stated price of $0.00 per share and received a separate grant of 1,337 shares at $10.90 per share.
To cover tax obligations on these vestings, the company withheld 5,510 shares at $12.82 per share, and the footnotes state that no shares were sold. After these transactions, she directly holds 1,762 shares of common stock and indirectly holds 25,949 shares through The Gasser Family Trust. A footnote also notes voluntary reporting of an acquisition under the company’s Employee Stock Purchase Plan for a period ending May 15, 2026.
Tandem Diabetes Care EVP & Chief Legal Officer Shannon M. Hansen reported routine equity compensation activity in company stock. On May 15, 2026, she exercised restricted stock units covering a total of 10,201 shares of common stock, and 5,192 shares were withheld by the company to satisfy tax obligations; footnotes state no shares were sold on the market. She also voluntarily reported acquiring 1,886 shares through the company’s Employee Stock Purchase Plan at $10.90 per share. Following these transactions, she directly holds 28,285 shares of common stock and indirectly holds 1,935 shares through the Shannon M. Hansen Trust.
Tandem Diabetes Care EVP & COO Jean-Claude Kyrillos reported routine equity compensation activity involving restricted stock units (RSUs), tax withholding, and an employee stock purchase. On May 15, 2026, 4,038 RSUs converted into common stock and 2,139 shares were withheld to cover taxes, with no shares sold. He also acquired 434 shares through the company’s employee stock purchase plan. Following these transactions, he directly holds 27,671 shares of Tandem Diabetes Care common stock.
Tandem Diabetes Care EVP & Chief Administrative Officer Susan Morrison reported a series of routine equity compensation transactions in company stock. She acquired 9,523 shares of common stock through the vesting and conversion of restricted stock units and 1,336 shares through the employee stock purchase plan at $10.90 per share.
To cover tax obligations on these vestings, 2,724 shares were withheld by the company, and no shares were sold on the open market. After these transactions, Morrison directly holds 43,708 shares of common stock.
Tandem Diabetes Care President and CEO John F. Sheridan reported routine equity compensation activity in common stock. On May 15, 2026, he acquired 1,336 shares at $10.90 per share through the company’s Employee Stock Purchase Plan. Several restricted stock unit awards vested and were exercised into a total of 51,189 shares of common stock. To cover related tax obligations, 24,773 shares were withheld by the company at $12.82 per share, and the footnotes state that no shares were sold on the market.
Tandem Diabetes Care EVP & Chief Financial Officer Leigh Vosseller reported several equity compensation transactions in company stock. On May 15, 2026, she exercised restricted stock units converting a total of 13,495 shares of common stock, and 4,843 shares were withheld by the company to cover tax obligations, with no shares sold. She also acquired 1,336 shares through the company’s Employee Stock Purchase Plan at $10.90 per share. Following these transactions, she directly holds 40,374 shares of common stock and an additional 25,580 shares are held indirectly through the Leigh A. Vosseller Trust.
Tandem Diabetes Care EVP & Chief Commercial Officer Mark David Novara reported routine equity compensation activity. On May 15, 2026, he acquired a total of 10,572 shares of common stock through the vesting and conversion of restricted stock units. To cover tax obligations on these vestings, 7,911 shares were withheld by the company at a reference price of $12.82 per share, and the footnotes state that no shares were sold in the market.
Tandem Diabetes Care EVP & Chief Operating Officer Jean-Claude Kyrillos exercised restricted stock units and had shares withheld for taxes. On April 15, 2026, he converted 3,636 restricted stock units into an equal number of common shares at a $0.00 exercise price under a long-term incentive plan.
To cover tax withholding on the RSU vesting, 1,926 common shares were withheld by Tandem Diabetes Care Inc. at $20.66 per share, with no shares sold on the market. Following these transactions, he directly holds 25,772 shares of common stock and 18,181 restricted stock units.
Tandem Diabetes Care EVP & Chief Commercial Officer Mark David Novara reported several equity transactions. He exercised 7,414 Restricted Stock Units into the same number of common shares at a $0.00 conversion price, reflecting RSU vesting under the company’s 2023 Long-Term Incentive Plan.
To cover taxes on this vesting, 5,540 shares of common stock were withheld by Tandem Diabetes Care Inc. at $21.59 per share; the footnotes clarify that no shares were sold for this tax-withholding disposition. Novara then executed a separate open‑market sale of 187 common shares at $23.05 per share on the following day.
After these transactions, he directly holds 37,656 shares of common stock. The filing notes that the open‑market sale was carried out under a Rule 10b5‑1 trading plan that Novara adopted on December 4, 2025, indicating the sale was pre‑scheduled rather than a discretionary trade.
Tandem Diabetes Care executive Mark David Novara, EVP & Chief Commercial Officer, sold 2 shares of the company’s common stock in an open-market transaction. The sale occurred at a price of $22.81 per share. After this small sale, he directly holds 35,969 shares of Tandem Diabetes Care common stock.
The transaction was executed under a pre-arranged Rule 10b5-1 trading plan that Mr. Novara adopted on December 4, 2025, which is designed to allow insiders to sell shares according to a predetermined schedule.
Tandem Diabetes Care Inc.'s Chief Technology Officer Rick Carpenter reported equity transactions tied to restricted stock units on February 17, 2026. He acquired 1,437 and 897 shares of common stock through exercises of restricted stock units at a price of $0.00 per share.
To cover tax withholding on these vestings, 808 and 504 shares of common stock were disposed of at $18.95 per share. According to the company’s disclosure, these shares were withheld by Tandem Diabetes Care Inc. to satisfy tax obligations and no shares were sold in the open market.
Tandem Diabetes Care executive Elizabeth Anne Gasser reported routine equity compensation activity. On February 17, 2026, she acquired 1,503 and 1,097 shares of common stock upon vesting and conversion of restricted stock units at a stated price of $0.00 per share.
To cover tax withholding on these vestings, 887 and 647 shares of common stock were withheld by the company at $18.95 per share; the footnotes state that no shares were sold in the market. After these transactions, she holds additional common stock indirectly, including 25,949 shares held by The Gasser Family Trust dated September 1, 2011, where she is a co‑trustee.
Tandem Diabetes Care executive Susan Morrison reported routine equity transactions related to restricted stock units. On February 17, 2026, she acquired a total of 2,600 shares of common stock through the exercise and vesting of RSUs, at no cash exercise price.
To cover tax withholding on these vestings, 882 shares of common stock were withheld by the company at $18.95 per share, and the footnotes state that no shares were sold on the market. After these transactions, she directly holds 42,635 shares of common stock.
Tandem Diabetes Care executive Mark David Novara reported equity award activity involving restricted stock units (RSUs) and common shares. On February 17, he exercised 77 RSUs, converting them into 77 shares of common stock at no exercise price under the company’s long-term incentive plan.
Of the resulting shares, 62 common shares were withheld by Tandem Diabetes Care to cover tax withholding obligations upon vesting of the RSUs, as disclosed in the footnotes, and no shares were sold on the open market. After these transactions, Novara directly held 35,971 shares of common stock and 380 RSUs.
Tandem Diabetes Care president and CEO John F. Sheridan reported equity compensation activity tied to restricted stock units (RSUs). On February 17, he acquired common shares through the exercise or conversion of RSUs, while a portion of the vested shares was withheld to cover tax obligations.
The filing shows tax-withholding dispositions of 1,963 and 2,400 common shares at $18.95 per share, with a footnote clarifying these were shares retained by the company to satisfy taxes and that no shares were sold on the open market.
Tandem Diabetes Care EVP & CFO Leigh Vosseller reported the vesting and exercise of restricted stock units into common stock, along with related tax withholding transactions. On February 17, 2026, 1,503 and 1,495 restricted stock units were converted into common shares at $0.00 per share. To cover tax obligations, 619 and 616 common shares were withheld at $18.95 per share, and a footnote states that no shares were sold. Following these transactions, Vosseller held 39,411 common shares directly and 25,580 common shares indirectly through the Leigh A. Vosseller Trust.
Tandem Diabetes Care executive vice president and chief legal officer Shannon Marie Hansen reported equity award activity involving restricted stock units and common stock. On February 17, 2026, several RSU awards vested and were converted into common shares at no exercise price.
Across these transactions, Hansen acquired common stock through derivative exercises coded "M" and had portions of the newly delivered shares withheld, coded "F", to cover tax obligations at $18.95 per share, with a footnote stating no shares were sold in the market. Following these movements, she directly held 23,276 shares of common stock. An additional 1,935 shares were reported as held indirectly through the Shannon M. Hansen Trust, where she serves as trustee.
Tandem Diabetes Care EVP & Chief Operating Officer Jean-Claude Kyrillos reported routine equity compensation activity. On 01/15/2026, 3,636 restricted stock units were converted into an equal number of common shares at an exercise price of $0. Of these, 2,118 shares were withheld by Tandem Diabetes Care to satisfy tax withholding obligations at $21.07 per share, and no shares were sold into the market. Following these transactions, Kyrillos directly held 24,062 shares of common stock and 21,817 restricted stock units, all under the company’s 2023 Long-Term Incentive Plan.
Tandem Diabetes Care Inc. executive vice president and chief commercial officer Mark D. Novara reported equity activity involving company stock. On 12/15/2025, 7,415 shares of common stock were acquired at an exercise price of $0 upon the vesting and settlement of restricted stock units granted under the 2023 Long-Term Incentive Plan. To cover tax withholding on this vesting, 3,843 shares were withheld by the company at a price of $22.11 per share, and no shares were sold into the market.
After these transactions, Novara directly beneficially owned 35,956 shares of Tandem Diabetes Care common stock and 29,658 restricted stock units, each representing a contingent right to receive one share of common stock or cash, in accordance with the plan’s terms.
Tandem Diabetes Care Inc. reported an insider equity transaction by its Chief Technology Officer, Rick A. Carpenter. On 12/15/2025, 406 restricted stock units (RSUs) granted on 12/15/2021 under the company’s 2013 Stock Incentive Plan were converted into common stock at an exercise price of $0.
To cover tax withholding on the RSU vesting, the company withheld 207 shares at a price of $22.11 per share, and no shares were sold on the open market. After these transactions, Carpenter directly holds 24,252 shares of Tandem Diabetes Care common stock.
Tandem Diabetes Care, Inc. (TNDM) reported an equity award to one of its directors on a Form 4. The director received 20,242 restricted stock units (RSUs) on November 7, 2025 under the company’s 2023 Long-Term Incentive Plan.
Each RSU represents a right to receive either one share of Tandem’s common stock or cash, at the company’s discretion, subject to the plan’s terms. The RSUs vest as to 33% of the total award on November 15, 2026, with the remaining units vesting in two equal annual installments after that date, contingent on the applicable conditions being met.
Tandem Diabetes Care Inc. (TNDM) reported equity compensation activity for an executive officer. The EVP & Chief Administrative Officer had restricted stock units (RSUs) convert into common stock on 11/17/2025, with 1,503 and 1,096 RSUs settled into shares at an exercise price of $0.
To cover tax withholding on these vestings, the company withheld 430 and 314 shares at a price of $18.61 per share, and no shares were sold into the market. Following these transactions, the reporting person directly beneficially owned around forty thousand shares of Tandem Diabetes Care common stock.
Tandem Diabetes Care Inc. (TNDM) reported insider equity activity by President & CEO and director John F. Sheridan. On 11/17/2025, restricted stock units (RSUs) granted under the company’s 2023 Long-Term Incentive Plan vested and were settled into common stock at no exercise price.
Following the vesting, 5,472 RSUs and 5,982 RSUs were converted into an equal number of common shares. To cover tax withholding on these RSU vestings, the company withheld 2,779 shares and 3,038 shares at a reference price of $18.61 per share; the filing states that no shares were sold. After these transactions, Sheridan directly owned 117,600 shares of common stock, plus 10,943 RSUs and 35,894 RSUs that remain outstanding and subject to the plan’s vesting schedule.
Tandem Diabetes Care (TNDM) executive vice president and chief strategy officer Elizabeth A. Gasser reported several equity transactions in the company’s stock. She voluntarily disclosed acquiring 586 shares of common stock at $15.59 through the company’s Employee Stock Purchase Plan for the May 16, 2025 to November 17, 2025 purchase period.
On the same date, 1,503 and 1,096 shares of common stock were delivered upon the vesting of previously granted restricted stock units, at an exercise price of $0. To cover tax withholding on these RSU vestings, the company withheld 805 and 587 shares at a price of $18.61 per share; no shares were sold into the market.
Following these transactions, Gasser directly beneficially owns 3,000 shares of Tandem Diabetes Care common stock and indirectly beneficially owns 22,949 shares through The Gasser Family Trust dated September 1, 2011, where she serves as co-trustee. The RSUs were granted under the company’s 2023 Long-Term Incentive Plan and vest over multi-year schedules.